Investor Relations

Our mission is simple—help patients across the globe who suffer from pain and chronic conditions. We are doing this by harnessing the power of nVNS, innovation, and technology to develop a safe and clinically backed treatment. Bringing new treatments to market will help improve patients' treatment options and lives.

News Releases

Date Title and Summary
Toggle Summary gammaCore® Receives FDA Clearance for the Acute Treatment of Pain Associated with Migraine Headache in Adult Patients
gammaCore® Receives FDA Clearance for the Acute Treatment of Pain Associated with Migraine Headache in Adult Patients Basking Ridge, NJ, January 29, 2018  – electroCore, LLC (electroCore), a commercial-stage bioelectronic medicine company, announced today that it has received 510(k) clearance from
Toggle Summary electroCore Completes $70 Million Series B Funding Round
Investment to fund commercialization of gammaCore ®  and further clinical development of nVNS   Basking Ridge, NJ, November 29, 2017  – electroCore, a U.S.-based bioelectronic medicine healthcare company advancing better patient therapies through superior approaches to neuromodulation, announced
Toggle Summary electroCore Announces Results from gammaCore® (non-invasive vagus nerve stimulator) Study in Migraine at the 18th Congress of the International Headache Society
PRESTO demonstrates clinical benefit of gammaCore in the acute treatment of migraine compared to sham  Basking Ridge, NJ, September 11, 2017 –  electroCore, a neuroscience and technology company dedicated to improving patient outcomes through technological advancement, announced the first results
Toggle Summary Publicis Health CEO Joins electroCore’s Board of Directors
Nick Colucci Brings Invaluable Healthcare Communications Expertise to Enhance electroCore’s Continued Growth   Basking Ridge, NJ, August 29, 2017 –  electroCore, a neuroscience and technology company dedicated to improving patient outcomes through technological advancement, today announced that
Toggle Summary gammaCore®, the First Non-Invasive Vagus Nerve Stimulator Applied at the Neck, Now Available for Adult Patients in the U.S.
electroCore launches gammaCore Patient Registry (GPR) to provide access to hand-held, easy-to-use device for the acute treatment of pain associated with episodic cluster headache in adults     Basking Ridge, NJ, July 18, 2017 –  electroCore, a neuroscience and technology company dedicated to
Toggle Summary electroCore Announces Appointment of New Chief Medical Officer
Peter Staats MD, MBA, ABIPP, FIPP Joins electroCore to Lead Global Development of Company’s Non-invasive Vagus Nerve Stimulation (nVNS) Therapy   Basking Ridge, NJ, June 21, 2017 –  electroCore, a neuroscience and technology company dedicated to improving patient outcomes through technological
Toggle Summary electroCore CEO to Join Company’s Board of Directors
Francis R. Amato to Take on Additional Role to Help Further Position the Company for Growth       Basking Ridge, NJ, June 21, 2017 –  electroCore, a neuroscience and technology company dedicated to improving patient outcomes through technological advancement, today announced that Chief Executive
Toggle Summary electroCore Receives 510(k) Clearance for gammaCore-S® (non-invasive vagus nerve stimulator) for the Acute Treatment of Pain Associated with Episodic Cluster Headache in Adult Patients
Regulatory clearance marks most recent achievement in new device being available to the approximately 400,000 Americans living with episodic cluster headaches     Basking Ridge, NJ, June 15, 2017 –  electroCore, a neuroscience and technology company dedicated to improving patient outcomes through
Toggle Summary New Analysis of ACT Clinical Trial Program Highlights Efficacy and Safety of electroCore’s gammaCore® (non-invasive vagus nerve stimulator) in the Acute Treatment of Episodic Cluster Headache
Data from Pooled Analysis of ACT1 and ACT2 To Be Presented in Late-Breaking Oral Session at Annual Scientific Meeting of the American Headache Society    Basking Ridge, NJ, June 8, 2017 –  electroCore, a neuroscience and technology company dedicated to improving patient outcomes through
Toggle Summary electroCore Announces Data Presentation at the 69th American Academy of Neurology Annual Meeting
Data from ACT2 Clinical Trial of gammaCore ®  in Cluster Headache Presented for First Time Yesterday During Emerging Science Session   Basking Ridge, NJ, April 26, 2017 –  electroCore, a neuroscience and technology company dedicated to improving patient outcomes through technological advancement,